The integrin a v b 3 is highly expressed in atherosclerotic plaques by medial and intimal smooth muscle cells and by endothelial cells of angiogenic microvessels. In this study, we have assessed noninvasive molecular magnetic resonance imaging (MRI) of plaque-associated a v b 3 integrin expression on transgenic ApoE 2/2 mice with a low molecular weight peptidomimetic of Arg-Gly-Asp (mimRGD) grafted to gadolinium diethylenetriaminepentaacetate (Gd-DTPA-g-mimRGD). The analogous compound Eu-DTPA-g-mimRGD was employed for an in vivo competition experiment and to confirm the molecular targeting. The specific interaction of mimRGD conjugated to Gd-DTPA or to 99m Tc-DTPA with a v b 3 integrin was furthermore confirmed on Jurkat T lymphocytes. . MRI evaluation was performed on a 4.7 T Bruker imaging system. Blood pharmacokinetics of Gd-DTPA-g-mimRGD were assessed in Wistar rats and in c57bl/6j mice. The presence of angiogenic blood vessels and the expression of a v b 3 integrin were confirmed in aorta specimens by immunohistochemistry. Gd-DTPA-g-mimRGD produced a strong enhancement of the external structures of the aortic wall and of the more profound layers (possibly tunica media and intima). The aortic lumen seemed to be restrained and distorted. Pre-injection of Eu-DTPA-g-mimRGD diminished the Gd-DTPA-g-mimRGD binding to atherosclerotic plaque and confirmed the specific molecular targeting. A slower blood clearance was observed for Gd-DTPA-g-mimRGD, as indicated by a prolonged elimination half-life and a diminished total clearance. Conclusion The new compound is potentially useful for the diagnosis of vulnerable atherosclerotic plaques and of other pathologies characterized by a v b 3 integrin expression, such as cancer and inflammation. The delayed blood clearance, the significant enhancement of the signal-to-noise ratio, and the low immunogenicity of the mimetic molecule highlight its potential for an industrial and clinical implementation.
Introduction
Atherosclerosis is an inflammatory disease that may persist for several years before the appearance of clinical manifestations such as heart attack, stroke, or peripheral arterial disease. In addition, many individuals develop coronary heart disease in the absence of abnormal lipoprotein profiles. Despite advances in treatment and preventive programmes, clinical complications of advanced atherosclerosis remain the primary cause of death in Western countries. 1 At present, clinicians do not dispose of reliable methods to characterize atherosclerotic plaque composition and current clinical decisions remain largely based on location and degree of stenosis. 2 Recent studies have shown that magnetic resonance imaging (MRI) could allow the differentiation of plaque components and the quantification of the degree of luminal narrowing. 3 However, acute coronary syndromes often result from plaque rupture at sites mostly normal or only characterized by modest luminal narrowing under angiographic examination. 4 Remodelling of the vessel wall often occurs at apparently normal sites, devoid of detectable stenosis. 5 In this context, there is an urgent need for diagnostic procedures dedicated to a specific identification of rupture-prone and vulnerable plaques, which are the most frequent cause of sudden cardiac events. 6 One of the most promising developments in vulnerable plaque diagnosis is the use of contrast agents able to specifically target plaque components, cell surface receptors, or other biomolecules. Indeed, the progression of atherosclerotic plaque disease involves a wide variety of biological mechanisms that could be visualized with targeted MRI or nuclear probes. 7 One of the most important hallmarks of atherosclerotic vessels is the development of microvascular networks of vasa vasorum extending deeply from the adventitia and outer media towards the intima. This mechanism of plaque angiogenesis seems to be activated by macrophages, T cells, and mast cells. The close proximity of plaque vessels to inflammatory cells and the expression of adhesion molecules on the endothelium of these microvascular networks suggest that they are regulated by a positive feedback mechanism. In addition, the development of such plaque microvessels could represent an essential requirement to sustain plaque growth by supplying oxygen and nutrients, which cannot reach anymore the deepest layers of the artery wall by simple diffusion. 8, 9 The integrin family of adhesion molecules is represented by heterodimeric glycoproteins composed of a and b subunits (currently 15 a and 8 b known subunits). In atherosclerosis, these adhesion molecules have distinct roles in inflammatory cell recruitment to the damaged vessel wall. Multiple ligands can bind to a v b 3 integrin in an Arg-Gly-Asp (RGD)-dependent manner. The integrin mediates cell locomotion and is also involved in cell migration through the extracellular matrix. [10] [11] [12] The integrin a v b 3 seems to be a critical molecule for several processes involved in atherosclerosis progression and in restenosis, e.g. smooth muscle cell (SMC) migration and angiogenesis, as suggested by its prominent expression on microvessels in the adventitia and in the plaque. 13 The a v b 3 integrin has been extensively investigated for imaging of tumour neovascularization.
14 For non-invasive molecular imaging of plaque-associated angiogenesis, Winter et al. 15 have developed a paramagnetic nanoparticle contrast agent targeted specifically to a v b 3 integrins. These nanoparticles were 273 nm in diameter, contained 94 200 Gd 3+ atoms per particle, and were characterized by a longitudinal relaxivity (r 1 ) of 17.7 s 21 mmol 21 L at 1.5 T and room temperature. Although very efficient from the relaxometric point of view, this contrast agent has the drawback of a large size that limits not only its blood clearance, but also its diffusion into the targeted tissue. 16 In fact, a v b 3 integrin is expressed both at the sites of angiogenesis and on SMCs accumulated in atherosclerotic plaques. 13 In the present work, we have assessed non-invasive molecular imaging of plaque-associated angiogenesis with a low molecular weight non-peptidic RGD mimetic 17, 18 conjugated to gadolinium diethylenetriaminepentaacetate (Gd-DTPA-g-mimRGD). The RGD mimetic has been reported to inhibit vitronectin and fibrinogen binding to the immobilized a v b 3 with an IC 50 of 3 Â 10 210 M. 17 This new compound, targeted to a v b 3 integrin, was evaluated by MRI in vivo in apolipoprotein E-deficient (ApoE 2/2 ) mice. The specific in vivo molecular targeting was confirmed by a competition experiment in the presence of the analogous compound Eu-DTPA-g-mimRGD. The specific interaction of mimRGD conjugated to Gd-DTPA or to 99m Tc-DTPA with a v b 3 integrin was furthermore confirmed on Jurkat T lymphocytes. Blood pharmacokinetics of Gd-DTPA-g-mimRGD were assessed in Wistar rats and in c57bl/6j mice.
Methods

Reagents
2-(4-Isothiocyanatobenzyl)-diethylenetriaminepentaacetic acid (p-SCN-Bn-DTPA) used to obtain Gd-DTPA-g-mimRGD was acquired from Macrocyclics (Dallas, TX, USA). RP-C18 stationary phase used for ligand purification was purchased from Merck (Darmstadt, Germany). IsolinkTM kit used to obtain 99m Tc-DTPA-g-mimRGD was purchased from Tyco Healthcare (Petten, The Netherlands). For Jurkat cell culture, the RPMI 1640 medium was obtained from Sigma-Aldrich (Bornem, Belgium), while the newborn calf serum (NCS) and the antibiotic-antimicotic were purchased from Invitrogen (Merelbeke, Belgium). To stimulate integrin expression, phorbol 12-myristate 13-acetate (PMA, Sigma-Aldrich) was used. GRGD peptide used for competition experiments was from MP Biomedicals (Brussels, Belgium) and from Bachem (Bubendorf, Switzerland). Sodium pentobarbital (Nembutal, Sanofi, Brussels, Belgium) was used to anaesthetize the animals. For immunohistochemistry, the following antibodies and reagents were used: rat anti-mouse integrin a v (CD51) monoclonal antibody (Chemicon, Heule, Belgium); rat anti-mouse PECAM-1 (platelet endothelial cell adhesion molecule-1, CD31) biotin-conjugated monoclonal antibody (Chemicon); rabbit anti-VCAM-1 (vascular cell adhesion molecule-1) polyclonal antibody (Santa Cruz Biotechnology, Heidelberg, Germany); rat anti-mouse Mac-3 antibody (Sanbio, Uden, The Netherlands); rabbit anti-rat biotinylated IgG, goat antibiotin IgG, and horse peroxidase-conjugated anti-goat IgG were from Vector Labconsult (Brussels, Belgium); biotinylated goat antirabbit IgG (Vector Labconsult); endogenous biotin blocking kit (Invitrogen); and streptavidin-linked peroxidase complexes (ABC kit, DakoCytomation SAS, Trappes, France).
2.2 Synthesis and physico-chemical characterization of DTPA-g-mimRGD complexed with Gd, Eu, or 99m 
Tc
The RGD mimetic (mimRGD) was obtained as described by Sulyok et al. 17 Synthesis was performed on a solid support using the Fmoc strategy. 18 The molecule was coupled with DTPA by reaction between p-SCN-Bn-DTPA and the mimetic in aqueous solution (pH 10.0) using a described procedure. 19 The ligand was purified by column chromatography on a RP-C18 stationary phase with H 2 O/methanol (50/50) as the mobile phase. DTPA-g-mimRGD ( Figure 1 ) was then complexed with GdCl 3 . 6H 2 O or with EuCl 3 . 6H 2 O. The absence of free lanthanide ions was checked with arsenazo (III) indicator. 20 The mass of the complexes was confirmed by ESI-MS. + solution of pH 10 (400-600 MBq), prepared using an Isolink TM kit, and heating the mixture for 30 min at 408C, yielding 80% of the technetium-99m tricarbonyl complex. Tc(CO) 3 DTPA, prepared as previously described, 20 was used as a reference and non-specific compound. Both Tc-compounds were analysed using the HPLC method described in ref. 21 in RPMI 1640 medium supplemented with 10% NCS and 1% antibiotic-antimicotic. Cells were resuspended in fresh culture medium prior to exposure to 50 ng PMA/mL for 3 h.
In vitro confirmation of integrin binding:
Gd-DTPA-g-mimRGD and 99m Tc-DTPA-g-mimRGD PMA-stimulated and control Jurkat cells (n = 6/experimental group) were incubated with MRI (2 Â 10 6 cells/mL; 4 mL/sample) contrast agents (0.4 mM Gd-DTPA-g-mimRGD and Gd-DTPA) or radioactive (10 6 cells/mL; 1.5 mL/sample) tracer agents (0.042 mM 99m Tc-DTPA-g-mimRGD and 99m Tc(CO) 3 -DTPA) in the culture medium. To confirm the specific binding to integrins, a competition experiment was performed with GRGD peptide at a concentration of 1.55 mM in the case of Gd-DTPA-g-mimRGD and of 2.5 mM in the case of 99m Tc-DTPA-g-mimRGD. After 2 h of incubation at 378C under mechanical agitation, the cells were rinsed three times with Tris-buffered saline (TBS) buffer (1 mM CaCl 2 , 2 mM MgCl 2 , 50 mM Tris-HCl, 150 mM NaCl, and 10 mM Hepes, pH 7.4) (centrifugation for 15 min at 4500 rpm).
For MRI and relaxometric analyses, the final pellet obtained after centrifugation was re-suspended (8 Â 10 6 cells/sample) in 0.1 mL 2% gelatin prepared in phosphate-buffered saline (PBS) (150 mM NaCl, 3.2 mM KCl, 6.4 mM Na 2 HPO 4 . 12 H 2 O, 1.5 mM KH 2 PO 4 , pH 7.4) and transferred into 0.2 mL PCR tubes. The samples were then analysed by MRI (Bruker AVANCE-200, 4.7 T, Bruker, Karlsruhe, Germany) using a RARE sequence (TR = 1048.5 ms, TE = 4 ms, RARE factor = 4, NEX = 4, matrix = 256, FOV = 3.5 cm, slice thickness = 1 mm, spatial resolution = 137 mm). The signal intensity (SI) of the images of cell samples was measured using the OSIRIS image analysis software, while their longitudinal relaxation rate values, R 1 (1/T 1 ), were determined at 60 MHz (1.5 T) on a Bruker Minispec mq60. Tc(CO) 3 -DTPA was measured using a Wallac 1480 WIZARD 3 00 automatic gamma counter (Perkin-Elmer, Boston, USA).
In vivo evaluation
All animal experiments were conducted in accordance with the requirements of the Ethics Committee of our institution. The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996).
Molecular targeting of atherosclerotic plaques by MRI
Animal model of atherosclerosis
Female C57bl/6 ApoE tm1unc mice, aged 15 months (n = 10), were acquired from Charles River Laboratories, Brussels, Belgium. The animals received a Western diet for 3 months before the MRI studies. For MRI experiments, the animals were anaesthetized with 50 mg/kg body weight, ip, of sodium pentobarbital. The contrast agents (Gd-DTPA-g-mimRGD and Gd-DTPA) were injected iv via a caudal vein at a dose of 0.1 mmol/kg. To confirm the specific targeting of a v b 3 integrins, an in vivo competition experiment (n = 4) was performed in the presence of Eu-DTPA-g-mimRGD, which was injected at a dose of 0.1 mmol/kg about 10 min before the administration of Gd-DTPA-g-mimRGD. All images were acquired at the level of the abdominal aorta.
MRI equipment and protocols
All experiments were performed on a 200 MHz (4.7 T) AVANCE-200 imaging system equipped with a vertical magnet and a microimaging device (Micro2.5AHS/RF, 25 mm coil). A test tube filled with a solution of 0.5 mM Gd-DTPA prepared in 2% gelatin was used as a reference.
The images were acquired with RARE (TR/TE = 1048.5/4 ms, RARE factor = 4, NEX = 4, matrix=256, FOV = 2. 
Image analysis
SI values for each time point were measured within regions of interest (ROIs) drawn manually by using the OSIRIS image analysis software in the arterial wall of the abdominal aorta. The ROIs were drawn on serial slices on the area of signal enhancement around the vessel lumen and were reproduced for pre-contrast images, where the aortic wall was not discriminated from the surrounding tissue. The ROIs drawn on a certain mouse were reproduced for each experiment when that animal was submitted to several types of studies, i.e. using Gd-DTPA-g-mimRGD, Gd-DTPA, or Eu-DTPA-g-mimRGD. SI enhancement (DSNR%) was calculated according to the following equation: DSNR% ¼ ðSI post =Noise SDÞ À ðSI pre =Noise SDÞ ðSI pre =Noise SDÞ Â 100
where SI post , post-contrast SI; SI pre , pre-contrast SI. The data were averaged and the standard error of the mean (SEM) was calculated for each time point.
Immunohistochemistry
Aorta specimens were collected subsequent to MRI evaluation. After fixation in 4% buffered paraformaldehyde solution, routine processing, and paraffin embedding, 5 mm thick sections were cut. After rehydration, endogenous peroxidases were blocked with 0.15% H 2 O 2 , while endogenous biotin was blocked with a blocking kit.
The expression of a v b 3 integrin and the presence of angiogenic blood vessels in aorta specimens were confirmed with rat antimouse integrin a v monoclonal antibody (10 mg/mL), rat anti-mouse PECAM-1 biotin-conjugated monoclonal antibody (5 mg/mL), and rabbit anti-VCAM-1 polyclonal antibody (2 mg/mL); the macrophages were detected with a rat anti-mouse Mac-3 (40 mg/mL).
The sections were incubated overnight with the primary antibodies and for 1 h with secondary IgG. Anti-CD51 and anti-Mac-3 were detected with biotinylated rabbit anti-rat IgG (10 mg/mL). This last one and biotinylated anti-CD31 antibody were followed by goat anti-biotin IgG (5 mg/mL) and horse peroxidase-conjugated anti-goat IgG (1 mg/mL). Anti-VCAM-1 antibody was detected with a biotinylated goat anti-rabbit IgG (10 mg/mL) followed by streptavidin-linked peroxidase complexes.
Finally, the sections were incubated 5 min with 50 mM Tris-HCl, pH 7.4, and then stained with 0.05% 3,3 0 -diaminobenzidine (DAB) completed with 0.02% H 2 O 2 in PBS. The sections were finally counterstained with hemalun and Luxol fast blue and mounted in a permanent medium.
PECAM-1 expression was also evaluated by a protocol adapted from Moulton et al., 8 where CD31 is stained on whole-mount aorta with biotinylated anti-PECAM-1 antibody (5 mg/mL, overnight), followed by streptavidin-linked peroxidase complexes. All incubations were carried out at 48C. For colour development, aortas were incubated with 0.05% DAB in 50 mM Tris, pH 7.4, for 5 min before adding 0.01% H 2 O 2 .
The controls were represented by aortas from healthy mice C57bl/6j and samples processed by the same protocols as above, except the primary antibodies.
Plasma pharmacokinetics
Plasma pharmacokinetics were assessed on Wistar rats (n = 8/group, weight 200 g + 50 g) and on c57bl/6j mice (n = 3/blood sampling, weight 24 + 3 g) (Harlan, Horst, The Netherlands) injected with contrast agents (Gd-DTPA-g-mimRGD and Gd-DTPA) at a dose of 0.1 mmol/kg body weight. Gadolinium content of the blood samples (collected through the carotid artery) was determined by relaxometry at 378C and 60 MHz on a Bruker Minispec. In the case of Wistar rats, a two-compartment distribution model was used to calculate the pharmacokinetic parameters: the elimination half-life (T e1/2 ), the steady-state volume of distribution (VD ss ), and the total clearance (Cl tot ). For c57bl/6 mice, the blood plasma concentration was measured at three time points (3, 30 , and 60 min, respectively) after the injection of contrast agents and the results were expressed as mmol/L. For each time point, the blood was sampled from a different mouse.
Statistical analysis
The mean + SEM were calculated for each experimental group and the statistical significance was evaluated with Student's t-test. The results were considered as significant for a P , 0.05.
Results
Physicochemical characterization of Gd-DTPA-g-mimRGD
The Gd-complex was characterized in vitro by relaxometry in aqueous solution. Proton longitudinal (r 1 ) relaxivity was measured at 378C on Bruker Minispecs PC-20 and mq60 (Bruker) and was found to be 4. Gd-DTPA-mimRGD-H2O = 1.4 + 0.02 ). Transmetallation by zinc(II) ions was evaluated by the decrease of the water longitudinal relaxation rate at 310 K and 20 MHz (Bruker Minispec PC 20) of buffered phosphate solutions (pH 7) containing 2.5 mM of the gadolinium complex and 2.5 mM of ZnCl 2 . 22 The results shown in Figure 2 indicate a higher stability of the complex Gd-DTPA-g-mimRGD in comparison with the parent compound, Gd-DTPA. Transmetallation of the gadolinium complex by diamagnetic Zn 2+ ions in a phosphate-buffered solution is reflected by a decrease of the proton relaxation rate [R 1 P (t)/R 1 P (0)] as a function of time.
In vitro validation of the specific interaction of mimRGD conjugated to DTPA (Gd-DTPA-g-mimRGD and 99m
Tc-DTPA-g-mimRGD) with integrins
Gd-DTPA-g-mimRGD was evaluated on Jurkat T cells to confirm the preservation of its affinity for integrins ( Figure 3A ). The MR image shows a higher signal enhancement produced by Gd-DTPA-g-mimRGD on PMA stimulated (0.038 s 21 ) ( Figure 3C ). The specific binding of DTPA-gmimRGD to Jurkat cells was furthermore confirmed (P , 0.01 vs. competing conditions and 99m Tc(CO) 3 -DTPA) after labelling with 99m Tc. 99m Tc-DTPA-g-mimRGD showed 31% lower binding levels in the presence of GRGD peptide ( Figure 3D ). Figure 4A shows axial slices at the level of abdominal aorta of an ApoE 2/2 mouse before and various times after the administration of Gd-DTPA-g-mimRGD. The external structures of aortic wall (tunica media and adventitia) were strongly enhanced 10 min post-contrast; although weaker, this enhancement was still present at 55 min. In the enlarged image of this anatomic slice (Figure 4B) , the contour of the atherosclerotic wall is visible along with the more profound layers (towards the aortic lumen) of the aortic wall (tunica media and intima). The aortic lumen seems to be restrained and distorted. It is remarkable that the spatial resolution of these images is in the micrometre range, i.e. 90 mm. The same mouse was injected with Gd-DTPA and the post-contrast image is shown in Figure 4 C. The anatomic slices are almost in the same position, by taking into account the spinal cord as a reference (the other organs change relatively their position). As compared with Gd-DTPA-g-mimRGD, the enhancement produced by the non-specific contrast agent Gd-DTPA is rather diffuse and the aortic wall is not clearly outlined.
Molecular imaging of atherosclerotic plaques with Gd-DTPA-g-mimRGD
The aorta localization was possible thanks to the MRI protocol 3D-TOF ( Figure 5 ), which has also evidenced the backward enhancement of the aortic wall (a clear spot towards the spinal cord). A comparison with the pre-contrast image clearly indicates that this particular enhancement was produced by the contrast agent. An in vivo competition experiment was designed to validate the specific integrin targeting at the level of atherosclerotic plaques by blocking the receptor with an analogous compound, Eu-DTPA-g-mimRGD, which should not have a significant effect on signal enhancement since its r 1 is very small. The contrast enhancement obtained in non-competing conditions ( Figure 6A ) is compared with that produced in this competition experiment ( Figure 6B ) and to the results obtained with the non-specific contrast agent Gd-DTPA ( Figure 6C) . The histological examination of abdominal aorta harvested after MRI session confirmed the presence of atherosclerotic lesion (disrupted media and thickened intima) and the expression of a v integrins ( Figure 6D ). Some structures in the disrupted media seem to have a lumen, which probably could be associated with angiogenic neo-vessels; most of them seem to be located at the intima-media border. 8 The signal enhancement of the aortic wall produced in competing or non-specific conditions is 40-90% lower than with Gd-DTPA-g-mimRGD. This effect was either global or restricted to a certain area of the aortic wall. This means that a certain fraction of the contrast agent (specific or non-specific) is free to circulate into the microvascular network of the aortic wall, which explains the relative signal enhancement produced by the non-specific compound, Gd-DTPA. Although low, such a nonspecific enhancement could represent a potential drawback for the specific diagnosis of atherosclerotic disease in this particular case. In clinical practice, this could be solved by subtracting the images obtained with a non-specific compound from the ones produced by the specifically targeted contrast agent. This procedure should allow the precise localization of pathological areas expressing the targeted receptor. An example of this type of image processing is shown in Figure 6 E along with colour-coded signal enhancement ( Figure 6F) , which highlights the areas of higher tissue enhancement.
The DSNR% is represented as a function of time in Figure 7 . Gd-DTPA-g-mimRGD produced at 42 min postcontrast a maximum signal enhancement (147%), which thereafter decreased progressively, although remaining at 97% 105 min post-contrast. In the presence of Eu-DTPAg-mimRGD, DSNR% did not surpass the level produced by the non-specific Gd-DTPA and ranged between 75 and 15%.
Immunohistochemistry
Immunohistochemistry studies on aorta specimens harvested after MRI sessions confirmed the expression of VCAM-1 ( Figure 8A ), PECAM-1 ( Figure 8B) , and Mac-3 ( Figure 8C ). VCAM-1 and PECAM-1 are often expressed around capillarylike structures, most of them located at the intima-media border. Mac-3 confirms the invasion of the aortic wall by macrophages, which were detected both in intima and in media layers. Figure 8D shows a control aorta harvested from a C57bl/6j mouse, immunostained for PECAM-1 expression. The internal elastic membrane is visible, with a scalloped appearance, and the endothelial cells (endothelial nuclei) appear to rest directly on it. No PECAM-1 expression could be detected on the endothelial layer probably because the integrity of endothelial cells was lost during histological processing.
The presence of vasa vasorum networks immunostained for PECAM-1 expression, which are probably angiogenic, was identified on whole-mount aorta from ApoE 2/2 mice ( Figure 8E ), but not on that from control c57bl/6j mice ( Figure 8F ).
Pharmacokinetic characterization
A slower blood clearance was observed for Gd-DTPAg-mimRGD, as proven by the prolonged T e1/2 and the diminished total clearance ( Table 1) . The VD ss of Gd-DTPAg-mimRGD is not significantly different from that of Gd-DTPA. In mice, the kinetics of blood plasma concentration ( Table 2 ) suggest a delayed clearance at 30 min (350 mmol/L for Gd-DTPA-g-mimRGD vs. 268 mmol/L for Gd-DTPA) and at 60 min (224 mmol/L for Gd-DTPA-g-mimRGD vs. 168 mmol/L for Gd-DTPA), respectively, after the injection of the contrast agents.
Discussion
The costs related to coronary heart disease and stroke in the USA were estimated to exceed 180 billion US$ in 2004. 23 In Europe, cardiovascular disease accounts for almost half of deaths and is estimated to cost the EU economy E169 billion/year. 24 Epidemiological studies have revealed that many patients with sudden cardiac events do not show preliminary cardiovascular symptoms. Accordingly, the diagnosis of vulnerable atherosclerotic plaques represents one of the main objectives in the prevention and treatment of cardiovascular disease.
Among the contemporary methods of medical imaging, MRI offers the unique advantage of being non-invasive and furnishing simultaneously, and with a high spatial resolution, anatomical, physiological, and molecular information. Nevertheless, the quite low efficiency of MRI contrast agents represents a challenge with respect to the choice of the most adequate method of chemical synthesis and to the development of MRI protocols adapted to their detection.
The MRI techniques using commercially available extracellular contrast agents have often improved plaque characterization. They helped discriminating the fibrous cap from the lipid core, while the degree of plaque enhancement was found to correlate with that of the neovascular network.
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Figure 8 Immunohistochemistry of VCAM-1 (A), PECAM-1 (B), and Mac-3 (C) expression stained in brown and dark-brown (pointed by arrows) in tunica media (M) and intima (In) on paraffin-embedded sections of aorta from ApoE 2/2 mice; no PECAM-1 expression could be detected on aorta from control C57bl/6j mice (D). The vasa vasorum networks (pointed by arrows), probably angiogenic, were immunostained for PECAM-1 expression on whole-mount aorta from ApoE 2/2 mice (E), but no evident vasa vasorum network could be observed on control aorta from C57bl/6j mice (F ); the arrow points to a branch of the aorta. The new generation of MR contrast agents dedicated to molecular imaging seems to be quite promising for the diagnosis of vulnerable plaques due to their vectorization with a molecular moiety able to target a pathologically overexpressed biomolecule. Due to the low tissue concentrations of these biomolecules, the current opinion is that the success of MR molecular imaging highly depends on the relaxivity of magnetic reporters. Higher proton relaxivity is often achieved by increasing the molecular mass of the paramagnetic contrast agent, which slows down its rotational motion. 27 The low molecular weight compounds represent a potential alternative, because their proton relaxivity will increase after target binding, enhancing thus the efficiency of MRI detection. A classical example is that of the blood-pool contrast agent MS-325, which shows a nine-fold increase of relaxivity in the albumin-bound form. 28 The low molecular weight MRI contrast agent developed in the present work was vectorized to a v b 3 integrin expressed in atherosclerotic plaques due to a RGD peptidomimetic that was conjugated to Gd-DTPA. Presenting a high specific affinity for a v b 3 integrin, the RGD mimetic is binding to PMA-stimulated Jurkat T lymphocytes with an apparent dissociation constant, K* d , of 1.13 Â 10 -8 M after conjugation to USPIO. 18 By considering the relatively small relaxivity of our integrin-targeted paramagnetic contrast agent and the receptor concentration (1.3 Â 10 28 M, if we consider 10 5 receptors/cell and 8 Â 10 6 cells/0.1 mL), the SI enhancement of cell samples is explained by the binding of Gd-DTPA-g-mimRGD to cell receptors, with a subsequent increase of relaxation rate resulting from the slowing down of its rotational motion. This is confirmed by the R 1
Norm measured at 1.5 T, since its value surpasses the one expected for a nanomolar concentration of the targeted receptors.
The competition experiment with the GRGD peptide confirmed the specific integrin binding of mimRGD to Jurkat T lymphocytes both when conjugated to USPIO (65-77% inhibition of binding), 18 Gd-DTPA (36% inhibition of binding) or to 99m Tc(CO) 3 -DTPA (31% inhibition of binding). In atherosclerotic plaques, the integrin a v b 3 is highly expressed by medial and intimal SMCs and by endothelial cells of angiogenic microvessels. 13 Our a v b 3 -targeted contrast agent, Gd-DTPA-g-mimRGD, strongly enhanced the external layers of the aortic wall, probably corresponding to the microvascular network of vasa vasorum. The more profound layers were also delineated, possibly as a result of a specific interaction with the targeted receptor expressed not only by angiogenic microvessels, but also by the intimal SMCs. The specific imaging of integrin expression is sustained by the lower and diffuse signal enhancement of the aortic wall produced in competing conditions or with a non-specific compound (Gd-DTPA). As shown above, part of the signal enhancement is produced by the free diffusion of the contrast agent through the microvascular network of the artery's wall. Such a potential drawback for the molecular imaging of any particular receptor could be solved in clinical practice by subtracting the images obtained with a non-specific compound from those produced by specifically targeted contrast agents. Another possible limitation is represented by the expression of a v b 3 integrin by both normal arteries and atherosclerotic plaques. 7, 13 Nevertheless, the implementation of contrast agents targeted to specific plaque constituents together with MRI morphometric techniques developed lately along with dedicated surface coils and high-field clinical systems could concomitantly allow the measurement of intima-media thickness and evaluate specifically the plaque's vulnerability. 2, 29, 30 The presence of atherosclerotic plaques was confirmed on histological specimens, which have shown the expression of a v integrins, VCAM-1 and PECAM-1, and probably the presence of angiogenic vasa vasorum networks. The immunostaining of these adhesion molecules was positive predominantly at the intima-media border around capillarylike structures, but also in the modified intima, although with a more sparse distribution. However, it has already been well documented that the expression of these adhesion molecules is not only an attribute of endothelial cells, but also of various leukocytes involved in the atherosclerotic lesion such as monocytes/macrophages, platelets and a subpopulation of T lymphocytes. The immunostaining of Mac-3 in our aorta specimens has confirmed the invasion of the aortic wall by macrophages. Our results corroborate the data in literature, where the role of angiogenesis in plaque progression and complication has been extensively investigated and confirmed both in humans and in ApoE 2/2 mice.
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The a v b 3 -targeted contrast agent is characterized by a slower blood clearance as compared with that of Gd-DTPA, which represents an advantage for molecular imaging of atherosclerotic blood vessels by extending the time-window of MRI scans. The significant enhancement of the signal/ noise ratio and the low immunogenicity of the mimetic molecule highlight its potential for an industrial and clinical implementation. Thus, the new contrast agent could contribute to high-resolution in vivo molecular imaging methods, aimed at the localization and quantification of unstable atherosclerotic lesions.
